<DOC>
	<DOC>NCT00959426</DOC>
	<brief_summary>PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics, of multiple oral doses of PF-04620110.</brief_summary>
	<brief_title>A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<criteria>Healthy male and/or female subjects between the ages of 18 and 55 years Body Mass Index (BMI) of 26.5 to 35.5 kg/m2; and a total body weight &gt;50 kg (110 lbs). Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>- Mutliple Ascending Dose Study in Overweight Subjects - Body Weight - Signs and Symptoms</keyword>
</DOC>